Stay updated with breaking news from Robert Bissonnette. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.
Researchers found that the percentage of patients with a PASI 75 response was higher among those receiving JNJ-77242113 vs placebo.
During this segment of his interview, Bissonnette discussed safety data on JNJ-2113 for patients with plaque psoriasis and later went into future research topics.
In this interview, Bissonnette spoke on the significance of the recent topline data on JNJ-2113 for patients with plaque psoriasis.
Percentage of patients with PASI-75 response was higher with the interleukin-23-receptor antagonist peptide.